Evaluation of lipid-bound sialic acid (LSA) as a tumor marker
Evaluation of lipid-bound sialic acid (LSA) as a tumor marker
复制标题
脂质结合唾液酸（LSA）作为肿瘤标志物的评价
DOI：
--
复制
发表时间：
1995
影响因子：
2
通讯作者：
A. Senra
中科院分区：
文献类型：
--
作者：
J. L. Saez;A. Senra
本研究的目的是评估作为癌症标志物的脂质结合唾液酸 (LSA) 的血清水平。这是一项病例对照研究，LSA 水平是通过病例和对照的盲法重复测定的。所有癌症病例的组织学验证用于确认诊断。该研究包括 135 名癌症患者（乳腺癌、头颈鳞状细胞癌、肺癌和胃肠道癌）和 95 名对照者（57 名正常受试者和 38 名患有慢性非恶性疾病的受试者）。通过 Katopodis 与间苯二酚的分光光度法测定标记物。 57 名健康个体的平均 LSA 水平为 15.09 mg/dl（95% C.I.，13.51-16.67），在 95 名非肿瘤个体的整个对照组中，该水平为 19.21 mg/dl（17.18-21.24），在 135 名癌症患者中，该水平为 26.64 mg/dl （24.42-28.87）。慢性非肿瘤疾病患者与健康个体之间以及癌症患者与健康个体之间存在统计学显着差异（p<0.001），但癌症患者与慢性非肿瘤疾病患者之间没有显着差异（p>0.05）。与肿瘤部位相关的平均LSA血清值为(mg/dl)：乳腺癌，21.49；胃肠道肿瘤，28.45；头颈癌，28.61，肺癌，32.54。根据临床分期的平均值为：完全缓解，18.50，显着高于健康对照（p<0.05）；局部疾病，23.50 (p<0.01)；局部区域疾病（p<0.05）；局部疾病，23.50 (p < 0.01)；局部区域疾病，27.21 (p < 0.001)；转移性疾病，34.49（p < 0.001），复发，20.87（p <0.05）。当将临床活动性癌症患者与健康人进行比较时，估计的临界值为 19.1 mg/dl，敏感性为 74.7%，特异性为 74.7%。我们得出的结论是，在临床活动性癌症病例中，LSA 值会增加，而在完全缓解的情况下，LSA 值会降低。 LSA作为肿瘤标志物对于诊断疾病程度具有重要价值。
The objective of this study is the evaluation of serum levels of lipid-bound sialic acid (LSA) as a of marker cancer. This is a case-control study, and the levels of LSA were determined with blinded duplicates of cases and controls. Histologic verification of all cancer cases was used to confirm the diagnosis. The study included 135 patients with cancer (breast carcinoma, head and neck squamous cell carcinoma, lung cancer and gastrointestinal cancer) and 95 controls (57 normal subjects and 38 with chronic non-malignant diseases). Marker determination was done by the spectrophotometric procedure of Katopodis with resorcinol. The mean LSA level in the 57 healthy individuals was 15.09 mg/dl (95% C.I., 13.51-16.67), in the entire control group of 95 non-tumoral individuals it was 19.21 mg/dl (17.18-21.24), and in the 135 cancer patients it was 26.64 mg/dl (24.42-28.87). There was a statistically significant difference between patients with chronic non-tumoral diseases and healthy individuals (p<0.001) and also between cancer patients and healthy individuals (p<0.001), but not between cancer patients and patients with chronic non-tumoral diseases (p>0.05). The mean LSA serum values related to tumor site were (mg/dl): breast cancer, 21.49; gastrointestinal tumors, 28.45; head and neck cancer, 28.61 and lung cancer, 32.54. The means according to clinical stage were: complete remission, 18.50, significantly higher than the healthy controls (p<0.05); local disease, 23.50 (p<0.01); locoregional disease, (p<0.05); local disease, 23.50 (p < 0.01); locoregional disease, 27.21 (p < 0.001); metastatic disease, 34.49 (p < 0.001), and relapses, 20.87 (p<0.05). When comparing patients with clinically active cancer with healthy persons, the estimated cutoff value was 19.1 mg/dl, with a sensitivity of 74.7% and a specificity of 74.7%. We conclude that LSA values increase in cases of clinically active cancer and decrease in complete remission. LSA is of great value as a tumor marker in the diagnosis of disease extent.
单克隆抗体可识别人黑色素瘤相关神经节苷脂中的 O-酰化唾液酸。
DOI：
--
发表时间：
1984
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
Cheresh,DA;Varki,AP;Varki,NM;Stallcup,WB;Levine,J;Reisfeld,RA
通讯作者：
Reisfeld,RA
测定血浆或血清中脂质结合唾液酸的改进方法。
DOI：
--
发表时间：
1980
期刊：
Research communications in chemical pathology and pharmacology
影响因子：
--
作者：
Katopodis,N;Stock,CC
通讯作者：
Stock,CC